JP2019034894A - Composition for promoting lipid metabolism - Google Patents

Abstract

To provide a composition for promoting secretion of glucagon in a subject with its lipid metabolism decreased, to promote the lipid metabolism, and food and drink containing the composition.SOLUTION: The present invention provides a composition for promoting lipid metabolism in a subject with its lipid metabolism decreased, the composition containing arginine, alanine and phenylalanine as active ingredients. When a total mol of all amino acids in the composition is 100 mol, a total mol of arginine, alanine and phenylalanine is 60 mol or more. There are also provided food and drink containing the composition.SELECTED DRAWING: Figure 4

Description

  The present invention relates to a composition for promoting lipid metabolism in a subject with reduced lipid metabolism, containing arginine, alanine and phenylalanine as active ingredients, and a food and drink containing the same.

  The obese population is steadily increasing with the westernization of eating habits and lifestyles. According to the Ministry of Health, Labor and Welfare “Summary of Results of National Health and Nutrition Survey (2010)”, the proportion of Japanese obesity is 30.4% for men and 21.1% for women. In addition, 11 million of the obese population, which has reached an estimated 23 million, has metabolic syndrome (lifestyle related diseases) such as hyperglycemia, hyperlipidemia, and hypertension, and the quality of life ( QOL) is greatly reduced. In the prevention and improvement of these diseases, not only the control of calorie intake through restriction of the amount of meal, but also the bioregulatory function by nutrients in food and the energy consumption by exercise have attracted much attention in recent years (Non-Patent Documents) 1).

  On the other hand, in recent years, the functionality of amino acids has attracted attention. For example, “Vespa Amino Acid Mixture (VAAM)”, which is an amino acid composition that reproduces the amino acid composition in saliva secreted by larvae, which are energy sources for adult hornets, It is known that medium lipase activity is increased and blood free fatty acids are increased (Patent Documents 1 to 3 and Non-Patent Document 2). Moreover, the lipid metabolism promoter at the time of the exercise | movement which mainly contains arginine, alanine, and phenylalanine is known (patent document 4). Moreover, an amino acid composition (Patent Document 5) containing arginine, glutamine, and branched chain amino acids in a certain amount or more is known. For the prevention, amelioration or treatment of metabolic syndrome, lipid metabolism abnormality or obesity, including specific amino acids that promote the secretion of glucagon involved in lipid metabolism, xanthine derivatives, isoflavones and carnitines or carnitine precursors A composition is disclosed, and arginine, alanine and leucine are disclosed as amino acids that promote glucagon secretion (Patent Document 6).

  However, it has not been known that a composition containing arginine, alanine and phenylalanine in specific amounts can promote glucagon secretion and promote (improve) lipid metabolism in subjects with reduced lipid metabolism. It was.

JP-A-4-112825 JP-A-6-24977 Japanese Patent Laid-Open No. 5-127258 JP, 2006-102064, A Japanese Patent Laid-Open No. 2005-27524 JP 2008-291002 A

Edited by Teruo Kawada, etc., supervised by the Japanese Society of Nutrition and Food, “Obesity and Fat Energy Metabolism: Strategies for Metabolic Syndrome”, Kenshisha, pp. 217-238 (2008) Tsuchita H et al., Effects of a Vespa amino acid mixture identical to hornet larval saliva on the blood biochemical indices of running rats., Nutr. Res., 17 (6), pp.999-1012 (1997)

  Under such circumstances, the present inventors have conducted intensive studies on materials that promote lipid metabolism in subjects with reduced lipid metabolism and efficiently reduce body fat. As a result, a composition containing high concentrations of the major dietary amino acids arginine, phenylalanine and alanine promotes glucagon secretion in subjects with reduced lipid metabolism, and has a high lipid metabolism promoting effect and anti-obesity It has been found that it works. Specifically, when a composition containing arginine, phenylalanine and alanine at a higher concentration than the conventional amino acid composition is administered to a subject with reduced lipid metabolism, the composition is not administered after administration. It was found that by carrying out low intensity exercise, secretion of glucagon was promoted and high lipid metabolism was observed. The present invention is based on such knowledge.

  Therefore, an object of the present invention is to provide a composition for promoting glucagon secretion in a subject with reduced lipid metabolism and, consequently, promoting (improving) lipid metabolism, and a food or drink containing the composition.

The present invention specifically provides the following inventions.
(1) A composition for promoting lipid metabolism in a subject with reduced lipid metabolism, containing arginine, alanine and phenylalanine as active ingredients, wherein the total number of moles of all amino acids in the composition is 100 moles The composition wherein the sum of the number of moles of arginine, alanine and phenylalanine is 60 moles or more.
(2) The composition according to (1), wherein the molar ratio of arginine, alanine and phenylalanine is 5.0 to 90.0: 5.0 to 90.0: 5.0 to 90.0.
(3) The composition as described in (2) whose molar ratio of the said arginine, alanine, and phenylalanine is 10.0-30.0: 20.0-60.0: 10.0-70.0.
(4) The composition according to any one of (1) to (3), wherein the total number of moles of arginine, alanine and phenylalanine is 90 to 100 moles when the total number of moles of all amino acids is 100 moles. object.
(5) The composition according to any one of (1) to (4), which enhances glucagon secretion.
(6) The composition according to any one of (1) to (5), for increasing the ratio of blood glucagon concentration to blood insulin concentration.
(7) Food / beverage products which contain the composition in any one of (1)-(6).
(8) The food or drink according to (7), which is any one form selected from the group consisting of beverages, granules, powders, and liquid foods.

  The composition for promoting lipid metabolism of the present invention promotes glucagon secretion, and can efficiently degrade lipids even in subjects who tend to have a slower and lesser lipid degradation than healthy subjects.

FIG. 2 is a schematic diagram showing a composition intake, blood collection and exercise schedule. It is a graph which shows the time-dependent change of the density | concentration of each component in the blood after a composition ingestion. It is a graph which shows the time-dependent change of the density | concentration of each component in the blood after a composition ingestion. It is a graph which shows the correlation with the ratio of the blood glucagon density | concentration with respect to the blood insulin level, and the blood total ketone concentration.

Detailed description of the invention

  Hereinafter, the present invention will be described in detail. However, the present invention is not limited to the following preferred embodiments, and can be freely changed within a range in which the effects of the present invention are exhibited.

  The composition for promoting lipid metabolism of the present invention (hereinafter also referred to as “the composition of the present invention”) contains arginine, alanine and phenylalanine as active ingredients.

  Arginine is one of the non-essential amino acids, and there are D-form and L-form. Cas No. of L-arginine. Is 74-79-3, and (S) -2-amino-5-guanidinopentanoic acid, (S) -2-amino-5- (amidinoamino) valeric acid, L-(+)-arginine or argin U Sometimes called. “Arg” or “R” may be used as an abbreviation for arginine. Arginine is easy to dissolve in water and formic acid, dissolves in dilute hydrochloric acid, and hardly dissolves in ethanol (16th revision Japanese Pharmacopoeia). Arginine is known to be contained in various materials and foods such as various proteins such as meat. Arginine is biosynthesized as an intermediate of the urea cycle, but it is rapidly decomposed, making it an essential amino acid in children. Arginine is known to be involved in promoting secretion of growth hormone and improving immune function.

  Alanine is one of the non-essential amino acids, and there are D-form and L-form. Cas No. of L-alanine. Is 56-41-7 and is sometimes referred to as (S) -2-aminopropionic acid, (2S) -2-aminopropanoic acid, α-alanine or L-(+)-alanine. “Ala” or “A” may be used as an abbreviation for alanine. Alanine is easily soluble in water and formic acid and hardly soluble in ethanol (16th revision Japanese Pharmacopoeia). It is known that alanine is contained in various materials and foods such as various proteins such as meat. Alanine is a kind of amino acid constituting proteins and is known to be a material for connective tissue.

  Phenylalanine is one of the essential amino acids, and there are D-form and L-form. Cas No. of L-phenylalanine. Is 63-91-2, (S) -α-aminobenzenepropanoic acid, (2S) -2-amino-3-phenylpropanoic acid, (S) -3-phenyl-2-aminopropionic acid, L- Sometimes referred to as β-phenylalanine or L-(−)-phenylalanine. “Phe” or “F” may be used as an abbreviation for phenylalanine. Phenylalanine is easily soluble in formic acid, slightly difficult to dissolve in water, soluble in dilute hydrochloric acid, and hardly soluble in ethanol (16th revision Japanese Pharmacopoeia). It is known that phenylalanine is contained in various materials and foods such as various proteins such as meat.

  The content of arginine, alanine and phenylalanine in the composition of the present invention is 60 moles or more and 70 moles or more when the total number of moles of all amino acids contained in the composition is 100 moles. Preferably, it is 80 moles or more, more preferably 90 moles or more, and particularly preferably 100 moles.

  The molar ratio of arginine, alanine and phenylalanine (arginine: alanine: phenylalanine) contained in the composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired, but 5.0 to 90.0: 5.0-90.0: 5.0-90.0 is preferable, 5.0-50.0: 5.0-50.0: 5.0-80.0 is more preferable. More preferably, it is 10.0-30.0: 20.0-60.0: 10.0-70.0, 19.5-20.4: 37.5-38.4: 41.5 It is even more preferable that it is ˜42.4, and it is particularly preferable that it is 20:38:42.

  The blending amounts of arginine, alanine and phenylalanine in the composition of the present invention can be appropriately determined according to the form of the composition, the age, weight and condition of the subject who takes the composition, and the use. The amount of arginine, alanine and phenylalanine in the composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired, but the total amount of arginine, alanine and phenylalanine in the composition is 0.2 to 100% by weight. It is preferable that it is 0.3 to 100 weight%, and it is especially preferable that it is 0.4 to 100 weight%.

  Arginine, phenylalanine and alanine contained in the composition of the present invention may be either D-form or L-form.

  Since arginine, alanine and phenylalanine are suitable for eating and drinking and oral intake because of their taste and smell, the composition of the present invention containing them at a high concentration is excellent in flavor. Therefore, the composition of this invention has the advantage that the flavor of the food-drinks and pharmaceutical which added this is not impaired.

  The composition of the present invention may further contain other amino acids in addition to arginine, phenylalanine and alanine. Other amino acids are not particularly limited as long as the effects of the present invention are not impaired, but include glycine, proline, lysine, tyrosine, threonine, leucine, valine, isoleucine, glutamic acid, tryptophan, histidine, serine, methionine, and aspartic acid. Can be mentioned. Any one kind of other amino acids may be contained in the composition of the present invention, or two or more kinds may be contained in combination.

When the composition of the present invention further contains other amino acids, the content of the other amino acids is not particularly limited as long as the effect of the present invention is not impaired, but the total number of moles of all the amino acids is 100 mol. In some cases, one or more of the other amino acids are each glycine 0.01-4 mol proline 0.01-4 mol lysine 0.01-2 mol tyrosine 0.01-2 mol threonine 0.01-2 mol Leucine 0.01-2 mol Valine 0.01-2 mol Isoleucine 0.01-2 mol Glutamic acid 0.01-1 mol Tryptophan 0.01-1 mol Histidine 0.01-1 mol Serine 0.01-1 mol Methionine 0.01-0.2 mol Aspartic acid is preferably contained in an amount of 0.01-0.1 mol.

  Arginine, phenylalanine, alanine and other amino acids contained in the composition of the present invention may all be in a free base form, and may be in the form of a hydrate or a salt. The salt is not particularly limited as long as the effect of the present invention is not impaired. For example, organic acid (acetic acid, tartaric acid, fatty acid, etc.), organic base, inorganic acid (hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, perchlorine) Acid) and salts with inorganic bases (potassium, sodium, zinc, etc.).

  In addition, arginine, phenylalanine, alanine and other amino acids contained in the composition of the present invention are obtained from known methods such as squeezing, concentration, purification, crystallization and extraction from materials and foods containing those amino acids. Can be obtained. Furthermore, what was produced using microorganisms and what was chemically synthesized can also be used. Solvents used for extraction from raw materials and foods are not particularly limited as long as the effects of the present invention are not impaired. For example, water, alcohols, hydrocarbons, organic acids, organic bases, inorganic acids, inorganics Solvents commonly used for extraction of bases and supercritical fluids can be mentioned. These solvent may be used individually by 1 type, and may be used in combination of 2 or more type.

  Further, the composition of the present invention may be further formulated with a pharmaceutically acceptable additive if desired, and the present invention includes such an embodiment. The pharmaceutically acceptable additive is not particularly limited as long as the effects of the present invention are not impaired. For example, excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspensions, etc. Agents, coating agents, solvents and tonicity agents. Moreover, as an agent containing the composition of this invention, the thing of dosage forms, such as a tablet (tablet), a capsule, a granule, a powder, a syrup agent, a liquid agent, and a suspension agent, is mentioned, for example. Furthermore, an appropriate amount of vitamins, minerals, organic acids, saccharides, peptides, and / or amino acids not listed above may be added to these agents as long as the effects of the present invention are not impaired. . In addition, these agents can be ingested or administered by routes such as oral, tube and intravenous.

  Moreover, the composition of this invention can take a various form, without being specifically limited unless the effect of this invention is impaired, It can be set as the form ingested suitably. Specifically, the composition of the present invention can take a solid form such as powder or granule, a paste form, a gel form, a liquid form or a suspension form.

  According to this invention, the pharmaceutical, food-drinks, nutritional composition, supplement, etc. which contain the composition of this invention are provided. Among these, foods and drinks containing the composition of the present invention are preferable, and examples of the foods and drinks include special-purpose foods, nutritional functional foods, nutritional supplements, health foods, pharmaceutical additives, foods for specified health use and Examples include functional foods. More specifically, various foods (milk, soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crusts, prepared milk powder, liquid foods, sick foods, nutritional foods, frozen foods, processed foods And other commercially available foods). In the present specification, “containing” the composition of the present invention includes the meanings of “including” and “using as a raw material” the composition of the present invention.

  Water, protein, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors, and the like can be blended in the food and drink containing the composition of the present invention. Examples of the protein include whole milk powder, skim milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, whey protein hydrolysate, α-casein, β-casein, κ -Casein, β-lactoglobulin, α-lactalbumin, lactoferrin, soy protein, chicken egg protein, meat protein and other animal and vegetable proteins, their degradation products, butter, whey minerals, cream, whey, non-protein nitrogen, sial Examples include various milk-derived components such as acids, phospholipids, and lactose. It may contain a peptide such as casein phosphopeptide or an amino acid. Examples of the saccharide include saccharides, processed starch (in addition to text phosphorus, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like. Examples of lipids include lard, fish oil and the like, animal oils and fats such as fractionated oil, hydrogenated oil and transesterified oil, palm oil, safflower oil, corn oil, rapeseed oil and coconut oil. Examples include vegetable oils such as fractionated oil, hydrogenated oil, and transesterified oil. Examples of vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline. And folic acid. Examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and the like. Examples of the organic acid include malic acid, citric acid, lactic acid, tartaric acid, erythorbic acid and the like. These components can be used alone or in combination of a plurality of types, and a synthetic product and / or a food containing a lot of these may be used. The form of these foods may be liquid, paste, gel, solid, powder or the like.

  The daily intake of the composition of the present invention can be appropriately determined according to the content of the active ingredient in the composition, the age, weight and condition of the subject who takes the composition, and the application. The daily intake of the composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired, but the total amount of amino acids contained in the composition is 0.3 to 30 g, 0. It is preferable that the intake amount is 8 to 8 g, 1 to 5 g, 1.3 to 3.5 g, 1.5 g, or 3 g.

  In addition, the composition of the present invention may be taken at the same time as a conventionally known food and drink or medicine having a lipid metabolism promoting effect, or before and after those intakes.

  The present invention relates to the use of arginine, alanine and phenylalanine (method of use) for producing a composition for promoting lipid metabolism, wherein the total number of moles of all amino acids in the composition is 100 moles. The use in which the total number of moles of arginine, alanine and phenylalanine is 60 moles or more is also included.

  Furthermore, the present invention includes a method for promoting lipid metabolism in a subject, comprising administering the composition of the present invention to the subject.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated more concretely, this invention is not limited by these Examples.

Glucagon secretion promotion and fat breakdown mechanism can be outlined as follows.
First, when glucagon binds to a receptor on an adipocyte membrane, adenylate cyclase existing on the inner surface of the cell membrane is activated, and cyclic AMP (cAMP) is synthesized from ATP. As a result of the increase in intracellular cAMP concentration, cAMP-dependent protein kinase A is activated, and this protein kinase A phosphorylates and activates hormone-sensitive lipase in adipocytes. Hormone sensitive lipase converts triacylglycerol to free fatty acid and monoacylglycerol. Monoacylglycerol lipase converts monoacylglycerol to glycerol and free fatty acids. Free fatty acids are taken up by cells and converted to acetyl-CoA by β-oxidation and further metabolized by the TCA cycle. At this time, excess acetyl-CoA is converted into a ketone body in the liver.

Example 1: Preparation of the composition of the present invention Arginine, alanine and phenylalanine in a molar ratio of 10:19:21 (total number of moles of arginine, alanine and phenylalanine when the total number of moles of all amino acids is 100 moles) 3 g of the mixture contained in 100 mol) was encapsulated in a capsule (Japanese Pharmacopoeia Cellulose White Capsule (vegetable), manufactured by Matsuya Co., Ltd.) to obtain the composition of the present invention. On the other hand, 3 g of dextrin (TK-16, manufactured by Matsutani Chemical Industry Co., Ltd.) was enclosed in a similar capsule to obtain a control composition.

Example 2: Comparison of lipid metabolism promoting effect of the composition of the present invention and the conventional amino acid composition In this example, the composition of the present invention prepared in Example 1 and the control composition were ingested respectively. The concentrations of glycerol, free fatty acids, TG, total ketone bodies, glucose, lactic acid, insulin, glucagon, growth hormone, adrenaline, noradrenaline and cortisol in blood were measured to compare and examine the effects of promoting lipid metabolism. This example was conducted as a double blind crossover comparative test.

  The present example was performed according to the schedule shown in FIG. 1 for middle-aged men (age 30 to less than 50) with obesity level I (BMI 25 to less than 30) who do not have exercise habits.

First, in FIG. 1, in VS0, blood was collected (10 mL) and urine was collected (10 mL) after a doctor's inquiry. Furthermore, bicycle exercise was performed, the time to 75% maximum heart rate was measured, and the maximum oxygen uptake (VO ₂ maximum) was estimated from the measured value and calculated. In addition, we confirmed the past history, the presence or absence of allergies, the intake of medicines / health foods, drinking / exercising habits, etc. in the preliminary questionnaire, and from these results, subjects who did not meet the “exclusion criteria” shown below were selected.
[Exclusion criteria]
・ Those who have a serious medical history and who are affected ・ Alcohol heavy drinkers (specifically, 2 units per day (40g of alcohol, 2 bottles of beer (1L), 2 sake (360mL)) Daily intake / ingestion of daily intakes, smokers, extremely irregular diets, shift workers and late-night workers, drugs that affect the test, health foods and supplements Persons (specifically, those who are taking or ingesting medicines and foods on a daily basis advocating cholesterol lowering action, neutral fat rise inhibiting action, and body fat reducing action)
・ People who donated blood within the last 6 months ・ Phenylketonuria and hyperphenylalaninemia ・ Others, based on the results of prior general blood tests and urinalysis Person

The background of 11 selected subjects is shown in Table 1.

For the selected subjects, the first test (VS1) was performed with an interval of 6 days or more from VS0. After providing a fasting time of 6 hours or more after intake of a diet (carbohydrate: lipid: protein ratio = 71: 16: 13), VS1 has two types of compositions (the composition of the present invention or the comparative example composition). One of them was ingested, exercised by bicycle and collected blood. Bicycle exercise was carried out at an exercise intensity (low intensity exercise) of 40% of the maximum oxygen intake (VO ₂ maximum) for 60 minutes from 30 to 90 minutes after ingestion of the composition. Blood was collected six times, 19 mL before ingesting the composition, 15 mL each at 30, 60, 90 and 120 minutes after ingesting the composition, and 19 mL at 150 minutes after ingesting, for a total of 98 mL. In VS1 and VS2, 200 mL of water was ingested after blood collection was completed 60 minutes after ingestion of the composition as a measure for dehydration of the subjects. In this example, the bicycle exercise was performed in a constant temperature and humidity laboratory under conditions of a temperature of 23 ± 2 ° C. and a humidity of 45 ± 5%.

  The second test (VS2) was performed with an interval of 6 days or more from VS1. In VS2, the composition of a group different from VS1 was ingested, and bicycle exercise and blood sampling were performed on the same schedule as VS1.

About each blood obtained by blood collection, the density | concentration of each component was measured with the following method, respectively.
The concentration of glucagon was measured by a double antibody radioimmunoassay using Glucagon RIA SML (Euro-Diagnostica AB).
The concentration of insulin was measured by chemiluminescence immunoassay using Architect Insulin (Abbott Japan Co., Ltd.).
Concentrations of glucose, total ketone bodies, glycerol and lactic acid were Iatro LQ GLU (manufactured by Unitika Ltd.), 3-HB Kainos (manufactured by Kainos Co., Ltd.), Glycerol Colorimetric Assay Kit (manufactured by Cayman Chemical) and Determiner-LA (Kyowa). Measured by an enzymatic method using Medex Co., Ltd.
The concentration of free fatty acid was measured by an enzyme-UV method using NEFA-SS Eiken (Eiken Chemical Co., Ltd.).
The concentrations of growth hormone and cortisol were measured by chemiluminescent enzyme immunoassay using Access hGH (Beckman Coulter, Inc.) and Access cortisol (Beckman Coulter, Inc.), respectively.
The concentrations of adrenaline and noradrenaline were measured by high performance liquid chromatography using HLC-725CA (manufactured by Tosoh Corporation).
The glycerol concentration was measured by consigning to IMU Co., Ltd. In addition, the concentrations of free fatty acids, TG, total ketone bodies, glucose, lactic acid, insulin, glucagon, growth hormone, adrenaline, noradrenaline and cortisol were measured by consigning to LSI Medience Corporation.

The time-dependent change of the measured value of each component in blood is shown in FIGS.
In addition, the measurement result of each component is shown as an average value ± standard deviation. In addition, a two-way analysis of variance of composition elapsed time and composition type was performed, and when there was an interaction, a Tukey method was used for comparison between groups.

  Further, the period was divided into before, during and after exercise, and Area Under the Curve (AUC) was calculated for each component. The AUC was determined by F-test to determine whether or not it was equivariant. In the case of equal variance, Student's t-test was performed, and in the case of unequal variance, Wilcoxon signed-rank test was conducted. P <0.05 was judged as a significant difference. The calculation results of AUC are shown in Table 2 and Table 3.

  As a result of two-way analysis of variance, there was an interaction in blood glucagon concentration. In addition, as shown in FIG. 3A, as a result of comparison between two groups by Tukey's method, a significant increase in blood glucagon concentration was confirmed in the group ingesting the composition of the present invention 30 minutes after ingestion of each composition. It was.

  In addition, as shown in Tables 2 and 3, in the group ingesting the composition of the present invention, the blood total ketone body concentration AUC and blood glucagon during exercise (30 to 90 minutes after ingestion of the composition) A significant increase in concentration was confirmed.

  On the other hand, the concentrations of glycerol, free fatty acids, TG, glucose, lactic acid, insulin, growth hormone, adrenaline, noradrenaline and cortisol in the blood have no interaction in the two-way analysis of variance and are also significant in the comparison between groups in AUC There was no significant difference.

  Since ketone bodies are produced by lipid metabolism (catabolism), the above results indicate that the intake of the composition of the present invention promotes lipid metabolism by low-intensity exercise. It can be said that this suggests that lipid metabolism can be efficiently promoted without imposing a burden on the body even in subjects who are difficult to exercise with high intensity, such as elderly people and obese people whose lipid metabolism has decreased.

  Furthermore, it has been shown that the composition of the present invention exhibits a lipid metabolism promoting effect without affecting the secretion of insulin, growth hormone adrenaline and noradrenaline. This can be said to suggest that side effects such as disruption of hormone secretion are unlikely to occur when the composition is ingested.

  Next, FIG. 4 shows the correlation between the ratio of blood glucagon concentration to blood insulin concentration and the total blood ketone concentration. Pearson's correlation coefficient was calculated for the correlation between the two.

  From the results of FIG. 4, a significant positive correlation (r = ratio) between the ratio of blood glucagon concentration to blood insulin concentration during exercise (blood glucagon concentration / blood insulin concentration) and blood total ketone body concentration. 0.44, p = 0.038). From these results, it was suggested that the composition of the present invention promotes lipid metabolism by promoting the secretion of blood glucagon concentration.

  According to the present invention, an agent for promoting lipid metabolism, a food and drink, a pharmaceutical, and the like that can effectively consume fat in a subject with reduced lipid metabolism and can be expected to have an effect of reducing body fat even by low-intensity exercise load Development is possible.

Claims (8)

  Arginine, alanine and phenylalanine as active ingredients for promoting lipid metabolism in subjects with reduced lipid metabolism, wherein the total number of moles of all amino acids in the composition is 100 moles , A total of moles of alanine and phenylalanine is 60 moles or more.   The composition of Claim 1 whose molar ratio of arginine, alanine, and phenylalanine is 5.0-90.0: 5.0-90.0: 5.0-90.0.   The composition according to claim 2, wherein the molar ratio of arginine, alanine and phenylalanine is 10.0-30.0: 20.0-60.0: 10.0-70.0.   The composition according to any one of claims 1 to 3, wherein the total number of moles of arginine, alanine and phenylalanine is 90 to 100 moles when the total number of moles of all amino acids is 100 moles.   The composition according to any one of claims 1 to 4, which enhances glucagon secretion.   6. The composition according to any one of claims 1 to 5, for increasing the ratio of blood glucagon concentration to blood insulin concentration.   Food-drinks which contain the composition as described in any one of Claims 1-6.   The food / beverage products of Claim 7 which are any one form selected from the group which consists of a drink, a granule, a powder, and a liquid food.

Images